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ABSTRACT Endogenous lung surfactant, and lung surfactant replacements used to treat respiratory distress syndrome, can
be inactivated during lung edema, most likely by serum proteins. Serum albumin shows a concentration-dependent surface
pressure that can exceed the respreading pressure of collapsed monolayers in vitro. Under these conditions, the collapsed
surfactant monolayer can not respread to cover the interface, leading to higher minimum surface tensions and alterations in
isotherms and morphology. This is an unusual example of a blocked phase transition (collapsed to monolayer form) inhibiting
bioactivity. The concentration-dependent surface activity of other common surfactant inhibitors including fibrinogen and
lysolipids correlates well with their effectiveness as inhibitors. These results show that respreading pressure may be as
important as the minimum surface tension in the design of replacement surfactants for respiratory distress syndrome.
INTRODUCTION
Human lung surfactant (LS) is a complex mixture of lipids
and proteins that forms a monolayer at the alveolar liquid-
air interface. This monolayer modulates the surface tension
of the lung, lowering the normal air-water surface tension of
70 mN/m to near zero on expiration, thereby stabilizing
alveoli against collapse during expiration and minimizing
the work of expanding the alveolar surface during inhalation
(Goerke, 1998). Lack of effective surfactant in premature
infants results in neonatal respiratory distress syndrome
(NRDS), a potentially fatal disorder characterized by re-
duced lung compliance and oxygenation (Spragg et al.,
1987). Transbronchial application of replacement LS (RLS)
preparations has proven a beneficial treatment, significantly
reducing mortality rates (Robertson, 1987; Gunther et al.,
1998). Currently, the most effective RLS come from animal
sources, but concern over potential viral contamination,
adverse immunological responses, and the limited supply of
animal surfactant (Spragg et al., 1987) drives continuing
research in synthetic RLS formulations.
Acute respiratory distress syndrome (ARDS), which af-
fects adults and children, has an incidence of 150,000 cases
per year in the United States and a mortality rate of 50%
(Hyers, 1991). ARDS has a more complicated pathology
than the simple absence of surfactant, but shares many
NRDS symptoms, such as diminished lung compliance,
marked restriction of lung volumes, and profound hypox-
emia largely attributable to shunting of blood past unventi-
lated lung units. Hence, it was hoped ARDS might respond
favorably to RLS therapy. However, clinical trials with the
most effective formulations used in NRDS yield gains in
ARDS patients that are both modest and transient (Spragg,
1991; Hyers, 1991; McIntyre et al., 2000). Extracted bron-
chial fluid (lavage) from ARDS patients consistently shows
elevated levels of serum proteins (Spragg, 1991; Nakos et
al., 1998), and the ratio of soluble protein to LS in lavage
correlates with severity and outcome in both NRDS and
ARDS (Hallman et al., 1987). ARDS lavage also has a
markedly reduced surface activity both in terms of the speed
with which it adsorbs to an exposed air-water interface and
the minimum surface tension achieved (Spragg, 1991). Bio-
physical studies of LS deliberately mixed with serum pro-
teins show that, at sufficiently high protein concentrations,
ARDS-like depression of RLS surface activity can be ob-
tained. Centrifugation, which removes contaminating cells
and proteins, restores normal surface activity in vitro (Holm
et al., 1985).
These observations suggest that serum proteins in the
lung can be a significant factor in the development of
ARDS. As serum proteins inactivate both endogenous and
replacement LS, serum proteins likely reduce RLS efficacy
in NRDS (Spragg, 1991). Unfortunately, the mechanism of
serum protein inhibition has remained obscure, frustrating
efforts to rationally construct RLS formulations appropriate
for ARDS. Current treatment consists of increased fre-
quency and dosage of surfactants designed for use with
NRDS, a regimen largely based on in vitro work showing
that an increased ratio of RLS to inhibitor protein favors the
competitive adsorption of RLS to the air-water interface
(Holm et al., 1990; Holm et al., 1999). However, to date this
therapy is no more successful than traditional RLS (Spragg
and Smith, 1998; McIntyre et al., 2000). Delivering the
amount of surfactant suggested for ARDS treatment by the
in vitro experiments may be difficult to achieve in practice,
especially in adults. For instance, Spragg (1987) suggested
that an expected adult dose of 50–200 mg/kg body weight
would require 23 h to deliver by aerosol. Other authors
have put the optimal therapeutic dose even higher, in the
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range of 200–800 mg/kg body weight (Gunther et al.,
1998).
RLSs consist primarily (98% by weight) of dipalmi-
toylphosphatidylcholine (DPPC), unsaturated phosphatidyl-
cholines and phosphatidylglycerols, fatty acids, and choles-
terol. There are often small fractions ( 2 wt%) of two
surfactant specific proteins, SP-B and SP-C (Tanaka et al.,
1986; Mizuno et al., 1995; Goerke, 1998). SP-B and SP-C
are difficult to isolate from natural sources, so most com-
mercial RLS formulations contain significantly lower
amounts of protein than do native surfactants (Spragg and
Smith, 1998; Mizuno et al., 1995). The composition of the
model surfactant used in this study is a simplified version of
the lipid composition of the clinically used RLS, beractant
(Survanta, Ross Products, Columbus, OH): 69% (w/w)
DPPC, 21% palmitoyl oleoyl phosphatidylglycerol (POPG),
and 10% palmitic acid (PA). However, there is a wide
variation in lipid and protein content between the various
replacement and native surfactants; the optimal LS compo-
sition has not yet been established (Bernhard et al., 2000).
We present Langmuir isotherms and fluorescence micro-
graphs showing that albumin concentrations above 0.1
mg/ml generate a surface pressure that exceeds the pressure
at which an overcompressed, or “collapsed” model RLS
monolayer reverts to the monolayer form or “respreads.”
Preventing respreading inhibits the control of interfacial
tension; surprisingly, it also disrupts the monolayer struc-
ture. This inhibition mechanism is independent of molecular
details; it arises solely from the concentration-dependent
surface activity of albumin and should therefore be appli-
cable to any other surface-active molecule. Indeed, in vivo
and in vitro inhibition by lysolipids and two other serum
proteins, immunoglobulin (Ig)G and fibrinogen, correlates
with their concentration-dependent surface activity (Holm
et al., 1999). Hence, the respreading pressure should be-
come an important consideration in the design of replace-
ment surfactants for respiratory distress syndrome.
MATERIALS AND METHODS
The Langmuir trough was milled from a solid piece of Teflon (DuPont,
Wilmington, DE) with a working surface area of120 cm2 and a subphase
volume of 150 ml (Lipp et al., 1997). A single Teflon barrier runs
linearly along the top edge of the trough and is driven by a motorized
translation stage. The barrier is spring-loaded against the trough and the
ends of the barrier in contact with the well edges are beveled at an angle
of 10° to minimize leakage of surfactant. Temperature control of the
subphase is achieved through the use of nine thermoelectric cooling ele-
ments. The trough can be operated over a temperature range of 10–50°C.
A simple feedback loop allows for measurement and control of the sub-
phase temperature. Expansion and compression speeds ranged from qua-
sistatic (30–60 min per expansion/compression cycle) to the maximum
speed available in our trough (30 s/cycle); no significant variations in the
isotherms were observed over these cycle times. AWilhelmy plate pressure
sensor with a filter paper plate (R&K, Wiesbaden, Germany) was cali-
brated before each experiment using the liquid expanded-liquid condensed
(LE-LC) kink of palmitic acid at 25°C (Peterson et al., 1992).
DPPC, POPG, and PA were purchased from Avanti Polar Lipids
(Alabaster, AL) and were used as received. Monolayers were made by
mixing 69 w/w% DPPC, 21 w/w % POPG, and 10 w/w% PA in a
1-mg/ml chloroform (Fisher Spectranalyzed) solution and spreading
onto a 25°C buffered subphase (pH 7 ( 0.2), 150 mM NaCl, 2.0 mM
CaCl2, 0.2 mM NaHCO3) in the Langmuir trough. The lipid mixture
was doped with 0.5–1 mol% of the fluorescent lipid Texas red 1,2-
dihexadecandyl-sn-glycero-3-phosphoethandamine (DHPE) (Molecular
Probes, Eugene, OR) to enable simultaneous fluorescence imaging and
isotherms. The fluorescent probe segregates to disordered or fluid
phases, which then appear bright in images; the probe is absent from the
solid or liquid condensed phases, which appear black or dark (Knobler
and Desai, 1992). Similar data taken at 37  0.5°C showed that the
isotherms and morphologies were essentially independent of tempera-
ture over this range.
For the experiments incorporating albumin in the subphase, 5.1 ml of
buffer was withdrawn from the subphase and 5.1 ml of a 50.8-mg/ml
bovine serum albumin (BSA) in buffer was injected beneath the collapsed
RLS monolayer. The barrier was stopped throughout injection and mixing
of the albumin. The final subphase concentration was 2.0 mg/ml BSA
doped with 2.2 w/w % napthenol-blue BSA (Molecular Probes) to permit
visual verification of subphase homogeneity. The RLS monolayer was held
well above the equilibrium spreading pressure of albumin during injection
and a 20-min post-injection mixing.
For fluorescence imaging, a Nikon Optiphot (Tokyo, Japan) with the
stage removed is positioned above the trough. Either a 5 or 40X power long
working distance objective designed for use with fluorescence systems is
used. The trough is mounted on a motorized xyz translation stage: the z axis
is used for focusing and the x and y axes are used to scan over different
regions. A 100-watt high-pressure mercury lamp was used for excitation. A
dichroic mirror/barrier filter assembly is used to direct the excitation light
onto the monolayer (with a normal angle of incidence) and to filter the
emitted fluorescence. The emitted fluorescence is collected by the objec-
tive and detected via a silicon intensified target camera (Dage-MTI, Mich-
igan City, IN). Images are recorded by a JVC (Yokohama, Japan) super-
VHS videocassette recorder and digitized via a Scion (Frederick, MD)
frame grabber.
RESULTS
Successive isotherms of this model RLS mixture (Fig. 1)
illustrate two crucial properties of an effective LS: a high
surface pressure at monolayer collapse and good retention
of material at the interface after collapse. To minimize the
work of breathing, an effective LS must have a high col-
lapse pressure (low minimum surface tension); this RLS
lipid mixture has a collapse pressure of 68 3 dyn/cm (n
20), close to the theoretical limit of 72 dyn/cm at 25°C.
Measurements within the alveoli of excised animal lungs at
functional residual capacity found a surface pressure of
63–67 dyn/cm (Schu¨rch et al., 1976, 1978), similar to the
collapse pressure of our model LS (Fig. 1). At collapse,
surfactant is forced from the monolayer into the subphase
with no further increase in the surface pressure (Fig. 1 B),
producing a plateau in the isotherm (Fig. 1 B on isotherm)
and the formation of multilayer folds in the monolayer
(Lipp et al., 1998).
Whether this collapsed material is lost to the subphase or
is drawn back onto the interface during expansion is crucial
to surfactant performance (Notter, 2000). LS monolayers
reside at the alveolar interface for hundreds of breathing
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cycles before replacement (Pison et al., 1996). Surfactant
respreading from the collapse structures to the useful mono-
layer may be estimated by comparing the onset area of
collapse in successive isotherms (Notter, 2000); for this
lipid mixture, the apparent recovery of the collapsed mate-
rial is quite high, 88  6% (n  17). The actual recovery is
likely higher as the small lipid fraction lost is most likely
because of leakage around the trough barriers at high sur-
face pressure. Fluorescence images of the RLS monolayer at
various points along the isotherm show the progression of
structural features. At 30 dyn/cm (A on isotherm) during the
compression limb of the cycle (Fig. 1 A, two magnifica-
tions) there is a bright, continuous network separating dark,
flower-like structures. The bright network consists of a
fluid- or liquid-expanded phase to which most of the fluo-
rescent dye segregates (McConnell, 1991), whereas the dark
domains are semicrystalline (Bringezu et al., 2001; Lipp et
al., 1998; Knobler and Desai, 1992). This morphology
seems to be the key to the desirable collapse properties of
RLS. The condensed-phase domains resist compression,
yielding a high collapse pressure, whereas the fluid network
allows the monolayer to fold continuously into a surface-
associated multilayer phase that can be drawn back onto the
interface during expansion. This large-scale buckling can be
seen in the bright lines crisscrossing the RLS monolayer at
collapse (Lipp et al., 1998; Diamant et al., 2000) (Fig. 1 B,
arrows). Similar collapse structures have been observed in
the clinical surfactant Survanta (Ding et al., 2001). Nearly
identical isotherms and morphologies were observed at
37°C, showing that the monolayer phase behavior was es-
sentially independent of temperature over this range.
Monolayer collapse is a first-order phase transition and
can be highly hysteretic. Thus, the multilayer folds in these
model RLS (Fig. 1 B) do not immediately return to the
monolayer when the surface pressure drops below the col-
column is higher magnification). The first compression-expansion cycle in
the isotherm is denoted by the solid curve, the second with a dashed line.
(A) At a surface pressure of 32 dyn/cm the characteristic morphology is of
a bright, liquid-expanded phase network surrounding dark, liquid-con-
densed domains. (B) At the “collapse pressure” of 68 3 dyn/cm (n 20)
the RLS can not maintain the monolayer structure and begins to buckle into
surface-associated multilayers, resulting in the bright lines in the micro-
graph. The fraction of this overcompressed material drawn back onto the
interface during expansion defines the percentage recoverability (%R). For
this mixture, each cycle is only slightly offset from the previous, indicating
that most material returns to the interface; in a set of 17 trials, an average
of 88 6% of the overcompressed material was recovered per cycle. Most
of the material is lost because of leakage around the trough barriers at this
low surface tension. Recovery begins when the collapse structures revert
back to the monolayer form of RLS. (C) The collapse structures begin to
convert to the monolayer when the surface pressure drops below 15
dyn/cm; the last bright line finally disappears at 5 dyn/cm. (D) Further
expansion leads to a uniform liquid-expanded phase. (E) Upon recompres-
sion, the monolayer reorganizes back into the network morphology (A) and
the cycle repeats.
FIGURE 1 Two successive surface pressure, , versus area per molecule
isotherms and corresponding fluorescence micrographs for the model RLS
composed of 69 w/w% DPPC, 21 w/w % POPG, 10 w/w% PA on a 25°C
buffered subphase (pH 7 ( 0.2), 150 mM NaCl, 2.0 mM CaCl2, 0.2 mM
NaHCO3) in a custom-built Langmuir trough (Lipp et al., 1997). Similar
isotherms and images taken at 37°C showed that the monolayer phase
behavior was essentially independent of temperature over this range. La-
bels A–E on the images refer to surface pressures on the isotherm. Images
were taken at two different magnifications at each surface pressure (left
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lapse pressure. In the initial phase of expansion, collapse
lines move apart but do not disappear, indicating that the
monolayer spreads without reincorporating the multilayer
material. In fact, reincorporation of the collapsed material
begins (Fig. 1 C, arrows) only after the surface pressure falls
below 15–20 dyn/cm. This appears as a sudden change in
the slope of the isotherm (Fig. 1 C). However, the last
collapse structures do not disappear until 5 dyn/cm. At
this surface pressure, the monolayer reverts to a uniform,
disordered state (Fig. 1 D). Upon recompression, the mono-
layer reorganizes into the characteristic fluid-network mor-
phology and the cycle repeats (Fig. 1 E).
When 2.0 mg/ml albumin is added to the subphase,
however, RLS activity is dramatically altered. Fig. 2 A
shows two compression-expansion cycles. At the end of the
collapse plateau of the first cycle (Fig. 2 A), the barrier was
stopped and sufficient albumin was injected and stirred
beneath the monolayer to achieve a subphase concentration
of 2.0 mg/ml. On expansion, the minimum surface pressure
of the monolayer was 14 dyn/cm (Fig. 2, A–C), approxi-
mately equal to the maximum surface pressure of a 2-mg/ml
albumin solution (Fig. 5). Recompressing the monolayer
produced the same collapse pressure but no overlap between
the two isotherms (Fig. 2, A–D). That is, the fraction of
collapsed material that returned to the monolayer dropped
from 90 to 0%.
The longer-term effects of albumin on RLS activity dem-
onstrate that this material loss is not through solubilization.
Fig. 2 B shows the maximum surface pressures achieved
during 6 h of RLS cycling on subphases with albumin
concentrations ranging from 0 to 2 mg/ml. Even for the
most concentrated albumin subphases, the maximum sur-
face pressure remains the same for several hours, indicating
that a significant fraction of the surfactant monolayer re-
mains at the interface. Solubilization, if it occurs, is ex-
tremely gradual and is unable to account for the 50% loss of
the monolayer in the 40 min between points A and D in Fig.
2 A. Moreover, because collapse pressure is a sensitive
function of composition (Notter, 2000), the stability of the
pressure maximum argues against selective solubilization of
a particular RLS component.
In fact, fluorescence micrographs clearly show that albu-
min acts by preventing the multilayer to monolayer transi-
tion upon expansion of the interface. The collapse folds and
surrounding monolayer are unchanged by the processes of
injection and mixing (postmixing photos in Fig. 3 A). How-
ever, now these multilayers remain intact up to the very
limits of trough expansion (Fig. 3 B), indicating that albu-
min interferes with the respreading mechanism of RLS. In
the next compression, the network structure begins to dis-
tort, especially near collapse structures persisting from the
previous cycle (Fig. 3 C). On the second cycle, new multi-
player folds form at the collapse pressure. These appear
distorted compared with first cycle collapse structures (Fig.
3 D, left and right column). After more than 12 h of cycling,
the network morphology (Fig. 1 A) has completely disap-
peared, but collapsed multilayers are still detectable (Fig. 3
E). As the collapsed structures are unable to modify inter-
FIGURE 2 (A) Isotherms and (B) maximum surface pressure vs. elapsed
time for the model RLS composed of 69 w/w% DPPC, 21 w/w % POPG,
10 w/w% PA on a 25°C buffered subphase before and after injection of
BSA. (A) The first cycle is denoted by the solid line, the second (postin-
jection) by the dotted line. The cycles show no overlap of the collapse
plateau (points A, D), indicating that no material returns to the interface
during the expansion of the interface after injection of albumin. The lowest
surface pressure obtained at maximum trough expansion increases from 0
without albumin (Fig. 1) to 14 dyn/cm (B). (B) Surface pressure at
minimum trough area for the RLS monolayer for 6 h after injection;
subphase albumin concentrations range from 0 to 2 mg/ml. Speed of area
dilation was 0.096 cm2/s for all cycles; each cycle took30 min. Note that
all concentrations require at least 2–3 h to significantly lower maximum
surface pressure. Because the impact is also not proportional to albumin
concentration (0.2 and 2 mg/ml show the same effect), it is clear that
solubilization is not important.
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facial tension, normal surfactant function is eventually lost
as is observed in vivo and in vitro.
The major features of inhibition can be reproduced on an
albumin-free subphase simply by not allowing the RLS
monolayer to reach the multilayer to monolayer transition
pressure, as shown in Fig. 4. During the initial compression,
the monolayer formed the characteristic network structure
(Fig. 4 A) and collapsed normally (Fig. 4 B). The interface
was then expanded only far enough to allow the surface
pressure to decrease to 15 dyn/cm and maintained at that
pressure. After 20 min, collapse structures were still clearly
visible and the monolayer network structure showed distor-
tion (Fig. 4 C) similar to that on albumin-containing sub-
phases (cf. Fig. 3 C). Distortion increased during recom-
pression and collapse (Fig. 4 D), and there was no overlap
between the first and second collapse plateaus (just as
observed when albumin fixed the minimum surface pres-
sure). Normal monolayer appearance (Fig. 4 E) and bioac-
tivity are restored (overlap of green and black plateaus in
isotherm) only when the monolayer was fully expanded so
that the multilayer-monolayer transition pressure is reached.
Inhibition is known to be strongly dependent on both the
species and concentration of inhibitor (Holm et al., 1990;
Fuchimukai et al., 1987). In Fig. 5, surface pressures of
fibrinogen, albumin, and IgG, three proteins commonly
implicated in surfactant inhibition, are given as a function of
concentration. The equilibrium surface pressure exerted by
a surface-active, soluble protein (or any other species) is a
logarithmic function of bulk concentration up to a certain
bulk concentration at which the surface becomes saturated
(Hiemenz, 1986). From Fig. 5, albumin and fibrinogen
concentrations 0.1 mg/ml and greater exert surface pres-
sures exceeding RLS respreading pressure, whereas IgG
requires 100 times that concentration to reach similar pres-
sures. Thus, albumin and fibrinogen should not inhibit much
below 0.1 mg/ml, and IgG should have little effect until 1
mg/ml or more. This prediction agrees well with our exper-
iments on albumin (Fig. 2 B) and with classic work (Seeger
et al., 1985) establishing the relative inhibitory capacity of
several serum proteins. In that work, albumin and fibrino-
gen were shown to be potent inhibitors requiring concen-
trations of just 0.1 and 0.01 mg/ml, respectively, whereas
IgG had little effect even at 1 mg/ml. This relationship
between inhibitory power and surface activity seems to hold
for nonprotein inhibitors as well. For lysopalmitoylphos-
phatidylcholine, the surface pressure at the surface satura-
tion concentration of 0.004 mg/ml is 34 mN/m (Yamanaka
et al., 1997), significantly above the monolayer respreading
pressure of 15 mN/m. Holm et al. (1999) showed that
lysophosphatidylcholine is a more potent inhibitor than
albumin, which requires a minimum concentration of 0.1
mg/m to reach a surface pressure of 15 mN/m.
DISCUSSION
LS isotherms are generally characterized by a significant
hysteresis between the compression and expansion cycles
(Goerke, 1998). One cause of this hysteresis is the forma-
tion of three-dimensional structures at the maximum or
“collapse” surface pressure on compression (Fig. 1 B),
which revert back to the monolayer at a significantly lower
respreading pressure on expansion (Fig. 1 C). For the model
FIGURE 3 Fluorescence micrographs for the model RLS on a 25°C
buffered subphase before and after injection of BSA to a final concentra-
tion of 2 mg/ml. Labels A–D correspond to points in the isotherm of Fig.
2 A. (A) Immediately after injection and mixing of albumin into the
subphase, the monolayer retains the network morphology typical of RLS
monolayers and similar collapse structures. (B) Collapse structures move
apart during expansion but do not release the overcompressed material
even at maximum trough area (arrows). In the absence of albumin, these
collapse structures begin to reincorporate their material during expansion.
(C) During the compression limb of the second cycle, the characteristic
network morphology begins to distort. This distortion is especially evident
near collapse structures persisting from the first cycle (arrows). (D) Newly
forming collapse folds appear more disordered and fragmented (arrows)
compared with collapse structures without albumin (Fig. 1) at both high
and low magnification. (E) After 12 h of cycling, the network morphology
has completely disappeared, but collapsed structures are clearly visible
(arrows).
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surfactant mixtures examined here, the collapse pressures
were 70 mN/m, whereas respreading began at 15–20
mN/m. If any other surface-active component is present at
sufficient concentration that its surface pressure exceeds the
respreading pressure of the monolayer, the transition from
the collapse structure to the monolayer is inhibited (Fig. 3
E). Albumin, fibrinogen, and lysolecithin are sufficiently
surface active that their surface pressure reaches 15–20
mN/m at physiologically relevant concentrations. Eventu-
ally, this inhibition causes more and more monolayer ma-
terial to be trapped in the collapse structures, and the ability
of the monolayer to lower surface tension is compromised
(Fig. 3 E).
However, relating the minimum surface pressure neces-
sary for respreading in vitro collapse structures to in vivo
lung function is complicated. The minimum static surface
pressure within excised lungs was measured to be 40
mN/m (surface tension of 30 mN/m) (Bachofen et al.,
1987; Schu¨rch et al., 1976, 1978), whereas the equilibrium
spreading pressure of natural and replacement surfactants
varies from 10–40 mN/m (Goerke, 1998; Schu¨rch et al.,
1976, 1978). To our knowledge, in vivo measurements of
dynamic alveolar surface tension during respiration have yet
to be performed, so the true range of surface pressures
obtained during breathing is unknown. In our experiments,
we dealt solely with monolayers spread from solvents with
no surfactant present in the subphase. Future experiments
should show if competitive adsorption of surfactant present
in the subphase will lead to a sufficient increase in the
respreading pressure to allow the collapse structures to
reincorporate into the monolayer even in the presence of
serum proteins.
The change in surface area of the lungs during breathing
is an important corollary to the range of surface tension
during breathing. When lung volume changes from 40 to
100% of total lung capacity, the lung epithelial cell basal
surface area increases 35% (Tschumperlin and Margulies,
1999). However, the actual area change of the air-fluid
FIGURE 4 Successive isotherms and fluorescence micrographs for the
model RLS on a 25°C buffered subphase. The monolayer is first com-
pressed to collapse (black dotted line); however, in contrast to Fig. 1, the
expansion is controlled so that surface pressure drops back to 15 dyn/cm
and maintained at that pressure for 20 min before recompression to the
same collapse pressure (red line). The monolayer is then fully expanded to
a surface pressure of zero and again compressed to collapse (green dotted
line). Labels A–E in the isotherm identify the images. (A) In the initial
compression, the characteristic morphology of a bright, liquid-expanded
phase network surrounding dark, condensed domains is seen at moderate
pressure. (B) The monolayer collapses at the expected pressure, forming
surface-associated multilayers. (C) After 30% overcompression, the
monolayer is expanded until the surface pressure drops to 15 dyn/cm. After
20 min at 15 dyn/cm, the collapse cracks remain but the network morphol-
ogy appears twisted and distorted, especially in the vicinity of cracks. (D)
This distortion worsens as the monolayer is recompressed to collapse. In
the isotherm, the new collapse plateau shows no overlap with the first
collapse plateau, confirming that the material sequestered in the collapse
structures in the first cycle is unavailable to subsequent cycles. Thus,
isotherms and images obtained on clean buffer with artificially elevated
surface pressure reproduce the essential features of isotherms and images
on a concentrated albumin subphase (Figs. 2 A and 3). (E) Fully expanding
the monolayer, which releases the material sequestered in the collapse
structures, restores morphology in the next compression normally.
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interface is more difficult to measure (Wirtz and Dobbs,
2000). The change in relative area in Langmuir isotherms is
arbitrary; the monolayer area can be changed sufficiently so
that the entire range between the collapse pressure and zero
surface pressure is recorded. The relative change in surface
pressure for a given change in area is typically much greater
on expansion than on compression of the monolayer (See
Figs. 1, 2, 4), especially after monolayer collapse. Hence, a
given change in area could result in a much larger change in
surface pressure depending on the history of the monolayer.
It is unclear if the change in surface area during normal
breathing would cause the collapse structures to occur or
disappear on each breathing cycle. Our observation that in
vitro surfactant recovery requires an area expansion suffi-
cient to reduce the surface pressure below 15–20 mN/m is
consistent with classic experiments by Mead and Collier
(1959) showing that diminished lung compliance caused by
mechanical ventilation with low and invariant tidal volumes
could be normalized by a single large inflation of the lungs.
Secretion of surfactant from the Type II cell is postulated to
be induced by deep sighing breaths and the resulting large
increases in lung surface area (Wirtz and Dobbs, 2000);
similar deep breaths could result in elimination of the col-
lapse structures in favor of monolayers as shown in Fig. 4.
The correlation between inhibitor surface activity and
degree of inhibition may prove to be general, i.e., that
concentration-dependent surface activity can be used as a
reliable predictor of inhibitory potential. It is unclear what
governs the respreading pressure of a particular surfactant
mixture. For instance, the LS proteins SP-B and SP-C affect
monolayer morphology and collapse and thus may have a
significant effect on respreading (Lipp et al., 1998; Ding et
al., 2001). However, our results show that the respreading
pressure of RLS should be an important design criterion in
developing new surfactants to resist inhibition. Altering the
surface activity of inhibitors by reducing inhibitor concen-
trations below the threshold concentration predicted by sur-
factant respreading pressure or by chemically altering in-
hibitor surface activity (Taeusch et al., 1999) might also
prove beneficial in eliminating inhibition.
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